On December 03, 2019, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) shares lost -47.01% or -4.16 points to close at $4.69 with a heavy trading volume of 3.785 million shares. It opened the trading session at $7.82, the shares rose to $8.1299 and dropped to $4.47, the range by which the price of stock traded the whole day. The company now has a market cap of $128 million and currently has 27.21 million outstanding shares. Protagonist Therapeutics, Inc. (PTGX) stock has plunged -65.13 percent of market value in 21 trading days.
PTGX stock’s trailing 3-year beta is 0, meaning there will be a lower rate of return, although posing a lower risk. The part of a firm’s profit given to each outstanding share of regular stock was -$2.95 share in the trailing 52 weeks. The stock’s value fallen -30.31 percent year to date (YTD) compared to a decline of -27.51 percent in 52 week’s period. The firm’s shares are still trading -71.87 percent below its 1-year high of $16.67 and -24.11 percent down from 52-week low of $6.18. The average consensus ranking on the company is 1.5, on a ranging where 5 is equal to a consensus sell rating. In other words, the mean analyst recommendations are ranking this stock as a buy.
Protagonist Therapeutics, Inc. (PTGX) is most likely going to rise 330.06 percent in the coming 12 months, as per price target approximations compiled by finviz. Nevertheless, they have set the price target at a $29-month high price target. This represents a whopping 518.34 percent increase from the current trading of shares. The 52-week median price target given by the analysts is $17.5, which means a return possibility of 273.13 percent in comparison with the closing price of the stock of $4.69 on December 03. The lowest price set for the stock is $17 — just above 262.47 percent from PTGX share price now.
Past records have indicated that shares in Protagonist Therapeutics, Inc. rose on 7 different earnings reaction days and we have yet to see whether this trend will play out and remain in place when the company reports upcoming earnings. Investors will get the next hint of PTGX’s Q4 earnings on March 04. Analysts are predicting revenue to climb 69.1 percent to $3.98M in the financial fourth quarter, while EPS will soar by about 8.77 percent to -$0.62 per share. In the last quarter, it earnings of -$0.61 per share came worse than the -$0.474, adjusted, expected by Thomson Reuters consensus estimate. Revenue for the quarter was $2.35M, missing the $5.97M analysts had expected. Earnings are seen to rise by 16.7 percent this year, 8.1 percent in the coming year.
Let’s take a glimpse at some insider activity at Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and observe the pattern. The earliest insider trade happened on 12/03/2019. Giraudo Bryan gathered a total of 8 thousand shares of the firm at average share price of $5.7. The total amount for the purchase was set at $45.6 thousand. On completing this exchange, the Director account balance was 18 thousand shares. The stock lost -17.72 percent from that insider purchase. On 12/03/2019, Gupta Suneel, EVP Clinical Operations, did a purchase of 30 thousand shares at a price of $5.13 per share. This increased 153.9 thousand shares to the insider’s fortune and the stock experienced a -8.58 percent retreat in price since the news became public. This exchange saw 49.5 thousand shares get into the EVP Clinical Operations account.
On 12/03/2019, CFO Kalkofen Donald A. recorded a purchase transaction valued at $5.99 thousand. The purchase at $5.1 a share has added 1.18 thousand shares into the insider’s portfolio position. Meanwhile, shares price witnessed -8.04 percent decrease since the transaction reporting date. The company insider is left with 1.18 thousand shares remaining in the account. PATEL DINESH V PH D, who works as President and CEO at the company, performed a purchase of 30 thousand shares in a transaction worth $168.6 thousand. The acquisition recorded on 12/03/2019 was priced at $5.62 per share. The stock price plunged -16.55 percent since the transaction. PATEL DINESH V PH D currently holds a stake of 409.82 thousand in PTGX stock which is worth $1.92 million after the insider buying.
The stock is lingering around the initial support level of $3.4. After this, the following support is at the zone of $2.1. Up until the time the PTGX stock hit levels beyond the current one, bulls should have no alarm. In terms of its momentum, the stock’s RSI hit 21.34 on the daily chart, and this may be a cause for comfort. In case the price goes below $2.1 level on closing basis, there may be more profit booking with the stock growing weaker. Still, getting to the $7.06 level may cause a pull-back move approaching $9.42 mark.